Monitor the Q3 2026 earnings release on November 5 for cash runway and pipeline updates, and the ALLO-329 data on November 9 for early efficacy and safety signals that could drive the stock.
Price Chart
Executive Summary
Allogene Therapeutics announced upcoming investor events for Q3 2026 financial results and the first clinical data from its ALLO-329 autoimmune disease program. The earnings release itself is not yet reported; this press release only schedules the events for November 5 and November 9, 2026.
Key Facts
- Q3 2026 financial results will be reported on November 5, 2026, after market close.
- Preliminary safety and efficacy data from the Phase 1 RESOLUTION study of ALLO-329 will be presented on November 9, 2026, at ACR Convergence.
- ALLO-329 is an investigational allogeneic CAR T targeting CD19 and CD70, incorporating Dagger technology.
- The RESOLUTION study includes adults with lupus, myositis, and scleroderma.
Financial Impact
No financial results reported in this press release; Q3 2026 results scheduled for November 5.
Risk Factors
- ALLO-329 is in early Phase 1; preliminary data may not be conclusive.
- Allogene is a clinical-stage biotech with no approved products; high reliance on pipeline success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391263 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | Press Release | $1.25 $1.18 | ▼ −5.60% | ▼ −3.83% | $1.18 (−5.60%) |
Oct 27, 2026 5d ago | SC 13G/A | $1.30 $1.25 | ▼ −3.85% | ▼ −3.46% | $1.18 (−9.23%) |
Oct 21, 2026 11d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.18 (−5.60%) |
Sep 2, 2026 8w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.18 (−40.40%) |
Aug 21, 2026 10w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.18 (−41.87%) |
Aug 21, 2026 10w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.18 (+43.54%) |
Aug 6, 2026 12w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.18 (−40.10%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.18 (+43.00%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.18 (+43.00%) |
May 28, 2026 22w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.18 (−45.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers